Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

[1]  J. Vose,et al.  Salvage second hematopoietic cell transplantation in myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  P. Bierman,et al.  Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America , 2013 .

[3]  C. Flowers,et al.  Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  P. Thall,et al.  Durable remission with salvage second autotransplants in patients with multiple myeloma , 2012, Cancer.

[5]  J. Perkins,et al.  Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  S. Trudel,et al.  Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Blough,et al.  Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  G. Morgan,et al.  Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  P. Vicini,et al.  Development of a Population Pharmacokinetics‐Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration , 2010, Journal of clinical pharmacology.

[10]  L. Escoda,et al.  Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study , 2010, Haematologica.

[11]  Mourad Tighiouart,et al.  A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study , 2010, Clinical Cancer Research.

[12]  B. Pégourié,et al.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). , 2010, Blood.

[13]  D. Porter,et al.  Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma , 2009, Bone Marrow Transplantation.

[14]  C. Frei,et al.  Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma , 2009, Leukemia & lymphoma.

[15]  J. McCune,et al.  Optimal Prevention of Seizures Induced by High‐Dose Busulfan , 2008, Pharmacotherapy.

[16]  S. B. Kangarloo,et al.  Therapeutic drug monitoring of busulfan in transplantation. , 2008, Current pharmaceutical design.

[17]  M. Terol,et al.  Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  E. Shpall,et al.  Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[20]  G. Saylors,et al.  Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  A. Piccin,et al.  Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma , 2006, American journal of hematology.

[22]  S. Trudel,et al.  Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation , 2005, Bone Marrow Transplantation.

[23]  Moo-Song Lee,et al.  Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation , 2005, Annals of Hematology.

[24]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[25]  A. Westfall,et al.  A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  J. Niland,et al.  Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  P. Thall,et al.  Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[29]  J. Gibbs,et al.  Plasma Concentration Monitoring of Busulfan , 2000 .

[30]  J. Miguel,et al.  Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma , 2000, British journal of haematology.

[31]  J. Wingard,et al.  Association of busulfan area under the curve with veno-occlusive disease following BMT. , 1996, Bone marrow transplantation.

[32]  L. Grochow.  Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. , 1993, Seminars in oncology.

[33]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.